Isotretinoin (Accutane): Who It’s For, Results, Risks and iPLEDGE

Isotretinoin (the drug once sold as Accutane) is the heavyweight of acne treatment, and it often gives long-lasting clearance. It’s meant for severe, scarring or stubborn acne, and a typical course runs about four to five months. It also comes with serious strings attached. It causes severe birth defects, which is why the US runs the iPLEDGE safety program, and it needs regular check-ins with a dermatologist. Here’s what the label, the guidelines and the best studies actually say, including the latest on iPLEDGE and the long-running question about mood.

What is isotretinoin, and who is it for?

Isotretinoin is an oral retinoid, a vitamin A–derived medicine. Its US label approves it for “severe recalcitrant nodular acne” in non-pregnant patients aged 12 and older, meaning acne with inflamed nodules 5 mm or larger that hasn’t responded to conventional therapy, including antibiotics (FDA-approved label).

In practice, dermatologists use it more broadly than that. The 2024 American Academy of Dermatology (AAD) guideline gives it a strong recommendation for severe acne, acne causing psychosocial burden or scarring, and acne that has failed standard treatment (Reynolds et al., JAAD 2024; Healio). The UK’s NICE guideline is more conservative. It suggests considering isotretinoin for severe forms such as nodulo-cystic acne, acne conglobata or acne at risk of permanent scarring, after adequate standard treatment. If you’re wondering whether your spots count, see my guides to cystic acne and the types of acne, or my overview of all acne treatment options.

How well does isotretinoin work?

This is where the evidence gets more interesting than the reputation. A 2018 Cochrane review pooled 31 randomized trials involving 3,836 people aged 12 to 55 (Costa et al., Cochrane 2018). Its key comparison wasn’t against placebo but against standard treatment. In three trials (400 people) that compared it with oral antibiotics plus topical treatment, there was no evidence that isotretinoin reduced inflamed spot counts more. It “may slightly improve (by 15%)” acne severity judged by a physician’s overall assessment. The reviewers rated the evidence as low quality for most outcomes, largely because of imprecision and dropouts.

That sounds underwhelming, but it mostly reflects a thin trial base rather than a weak drug. The same review found that higher doses beat very low ones, and that continuous daily dosing improved acne more than intermittent (for example, once-weekly) dosing at 24 weeks. The AAD’s own patient guidance says treatment “often results in prolonged clearance of acne, which can be permanent for some patients” (AAD). Honest summary: clinicians and guidelines are confident in it, but the formal trial evidence is lower quality than you’d expect for such a widely used drug.

How is it taken, and how long does a course last?

The label’s usual dose is 0.5 to 1 mg per kilogram of body weight per day, split into two doses, for 15 to 20 weeks. Very severe cases may go higher. If a second course is needed, the label calls for a break of at least two months first (FDA-approved label). The AAD says one course takes about four to five months, and prescriptions cover only 30 days at a time, so you’ll see your dermatologist monthly (AAD).

You’ll also have blood tests. The label notes that about a quarter of patients develop raised triglycerides (blood fats) and that liver enzymes can rise, so lipids and liver tests are checked (label). StatPearls says liver function and lipids should be monitored until a response to the drug is established (StatPearls). Ask your prescriber how often they test, as practice varies.

What are the side effects?

Almost everyone gets some dryness. StatPearls describes dry, cracked lips (cheilitis) as the most common side effect, affecting about 90% of patients (StatPearls). The label’s most common side effects (5% or more) include dry lips, dry skin, back pain, dry eyes, joint pain, nosebleeds, headache and cold-like symptoms (label). The AAD notes these are usually manageable and typically settle after treatment ends (AAD). A good moisturizer and sunscreen routine and lip balm become non-negotiable.

Less common but important warnings on the label (FDA-approved label) include:

• Raised pressure in the skull (pseudotumor cerebri). Isotretinoin shouldn’t be combined with tetracycline antibiotics such as doxycycline.
• Decreased night vision, which may persist after treatment.
• Bone effects, including reduced bone density.
• Inflammatory bowel disease: the label says to stop if symptoms occur. However, StatPearls says recent meta-analyses have not shown an association (StatPearls), and the AAD says more research is needed (AAD).
• No blood donation during treatment and for one month after.

Does isotretinoin cause depression or suicide?

This is the fear I hear most, so I read the evidence carefully. The label carries warnings about depression, psychosis and suicidal thoughts, and asks prescribers to monitor for them (label). But the large studies are reassuring.

• A 2017 meta-analysis of 31 studies in the Journal of the American Academy of Dermatology found that the prevalence of depression declined after isotretinoin treatment (risk ratio 0.588), and depression scores fell from baseline (Healio summary).
• A 2023 JAMA Dermatology meta-analysis of 25 studies with over 1.6 million participants found the one-year absolute risks of completed suicide, suicidal thoughts and self-harm were each under 0.5%, and found no association between isotretinoin and psychiatric disorders overall. Its authors still urged clinicians to “monitor patients for signs of mental distress” (Medical Xpress summary of Tan et al.).

The AAD points out that severe acne itself can raise the risk of mood changes (AAD). Still, individual reactions can’t be ruled out. StatPearls says screening for depression, suicidal thoughts and past suicide attempts should happen before prescribing (StatPearls), and NICE advises taking a person’s psychological wellbeing into account and referring to mental health services first if appropriate (NICE NG198). If your mood drops on treatment, tell your prescriber straight away. That’s exactly what the monthly visits are for.

What is iPLEDGE, and what’s changing in 2026?

Isotretinoin “can cause life-threatening birth defects and is contraindicated in pregnancy” (label). The FDA’s iPLEDGE program exists to “mitigate the risk of embryo-fetal toxicity” and covers all approved isotretinoin products (FDA). Under the label, people who can get pregnant use two forms of contraception together from one month before, during, and for one month after treatment, with regular pregnancy tests (label).

The program has long been criticized as burdensome, and it’s in the middle of a change. Here’s the timeline from the FDA’s iPLEDGE page (current as of June 16, 2026):

The AAD welcomed the February 2026 approval (Healio). Because dates have already shifted once, check with your prescriber or pharmacy about which rules apply when you start.

Will acne come back after isotretinoin?

For some people, yes. The best recent data comes from a 2025 JAMA Dermatology study of 19,907 US patients with at least a year of follow-up (average about 25 months) (Lai and Barbieri, 2025). “Relapse” here meant being prescribed another systemic acne treatment, such as an antibiotic, spironolactone or isotretinoin.

• 22.5% had a relapse by that definition.
• 8.2% went on to a second course of isotretinoin.
• Higher cumulative doses were linked to lower relapse, but the benefit didn’t extend beyond about 220 mg/kg.
• Female patients were more likely to relapse than male patients (Healio).

This is a claims-database study, so it shows associations rather than proof. Still, it suggests most people don’t need further systemic treatment in the following couple of years. For many, a topical maintenance routine afterwards helps. See my simple acne routine and, for women, adult hormonal acne routine.

Frequently asked questions